Page last updated: 2024-09-03

tazobactam and E coli Infections

tazobactam has been researched along with E coli Infections in 43 studies

Research

Studies (43)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	4 (9.30)	18.2507
2000's	10 (23.26)	29.6817
2010's	21 (48.84)	24.3611
2020's	8 (18.60)	2.80

Authors

Authors	Studies
Abe, T; Ado, M; Agarwal, A; Dos Santos, O; Francisco, G; Gu, Y; Knox, JR; Kumagai, T; Li, Z; Lin, YI; Mansour, TS; Petersen, PJ; Shlaes, DM; Sum, FW; Tsuyoshi, T; Ushirogochi, H; Venkatesan, AM; Weiss, WJ; Yamamura, I; Yang, Y	1
Cauda, R; D'Inzeo, T; De Pascale, G; Fadda, G; Fiori, B; Leone, F; Rossi, M; Sali, M; Sanguinetti, M; Spanu, T; Trecarichi, EM; Tumbarello, M	1
Almind, SR; Andreasen, MR; Frimodt-Møller, N; Hansen, KH; Hertz, FB; Jelsbak, L; Nielsen, KL; Schønning, K	1
Deligios, M; Fiamma, M; Paglietti, B; Rubino, S; Sacarlal, J; Santona, A; Simbine, SE; Sumbana, JJ; Taviani, E; Zimba, T	1
Dong, L; Feng, J; Geng, H; Gu, S; He, C; Hou, G; Ji, T; Kang, W; Lai, J; Li, Y; Li, Z; Pang, D; Wang, Y; Zhao, L; Zhu, X; Zhu, Y	1
Caljon, B; Crombé, F; De Geyter, D; Demuyser, T; Janssen, T; Muyldermans, A; Piérard, D; Seyler, L; Vanstokstraeten, R; Wybo, I	1
Karlowsky, JA; Kazmierczak, KM; Motyl, MR; Sahm, DF; Young, K	1
Canovas, J; Chau, F; Fantin, B; Le Monnier, A; Lefort, A; Petitjean, G	1
Adams, ER; Bulgasim, I; Corless, C; Edwards, T; Fraser, AJ; Howard, A; Hubbard, ATM; Mason, J; Parry, CM; Roberts, AP; Roberts, P; van Aartsen, J	1
Cisera, K; Hughes, C; Rogers, B; Taylor, L; Xie, O	1
Kim, HS; Kim, HY; Kim, YK; Lee, J; Lee, JA; Lee, SS; Seo, YB; Song, W; Uh, Y	1
Bailoor, K; Chen, T	1
Ali, I; Shabbir, M	1
Bansal, N; Gopalakrishnan, R; Kumar D, S; Nambi, PS; Ramasubramanian, V; Sukhwani, KS	1
Caro, L; Huntington, JA; Long, J; Xiao, AJ	1
Johnson, JR; Johnston, BD; Thuras, P	1
Bernhardt, M; Boschert, EN; Dubin, JR; Lauer, MF	1
Nordmann, P; Ortiz de la Rosa, JM; Poirel, L	1
Ann Justo, J; Bookstaver, PB; Elizabeth Davis, S; Foster, R; Gould, A; Ham, J; Hucks, J; Nicolau, DP	1
Choi, EH; Lee, HJ; Lee, J; Oh, CE	1
López-Cerero, L; Muniain, MA; Pascual, Á; Retamar, P; Rodríguez-Baño, J	1
Ambrose, PG; Bhavnani, SM; Bulik, CC; Castanheira, M; Forrest, A; Friedrich, LV; Jones, RN; Mendes, RE; Nicasio, AM; Okusanya, OO; Steenbergen, JN; VanScoy, B	1
Ambrose, PG; Bhavnani, SM; Bulik, CC; Forrest, A; Friedrich, LV; Jones, RN; McCauley, J; Mendes, RE; Okusanya, OO; Steenbergen, JN; Vanscoy, B	1
Bush, K; Bussell, B; Clugston, SL; Estabrook, M	1
Davin-Regli, A; Franceschi, C; Pagès, JM; Pinet, E; Zambardi, G	1
Arakawa, Y; Fujita, A; Jin, W; Kimura, K; Mikamo, H; Suematsu, H; Wachino, J; Yamada, K; Yamagishi, Y; Yokoyama, S	1
Bliss, CA; Cloutier, D; Hershberger, E; Huntington, JA; Kaye, KS; Miller, B; Paterson, DL; Popejoy, MW; Steenbergen, JN; Umeh, O	1
Church, DL; Gregson, DB; Laupland, KB; Le, P; Pitout, JD	1
Calcinari, A; Casteletti, S; Cirioni, O; Ghiselli, R; Giacometti, A; Guerrieri, M; Kamysz, E; Kamysz, W; Orlando, F; Rimini, M; Silvestri, C; Tocchini, M	1
Ge, Y; Giske, CG; Karlsson, IM; Titelman, E	1
Bulik, CC; Keel, RA; Nicolau, DP; Sutherland, CA; Tessier, PR	1
Bilker, WB; Edelstein, PH; Han, JH; Kasahara, K; Lautenbach, E	1
Gesser, RM; McCarroll, K; Teppler, H; Woods, GL	1
Bethel, CR; Bonomo, RA; Helfand, MS; Hujer, AM	1
Derendorf, H; Liu, Q; Rand, K	1
Harada, AS; Lau, W	1
Abbruzzetti, A; Cirioni, O; Di Matteo, F; Ghiselli, R; Giacometti, A; Mocchegiani, F; Orlando, F; Saba, V; Scalise, G; Silvestri, C	1
Barnaud, G; Chevrel, G; Dreyfuss, D; Eveillard, M; Meybeck, A; Mounier, R; Ricard, JD	1
Alós, JI; Gómez-Garcés, JL; Mateos, MV	1
Duncanson, FP; Norden, CW; Talan, DA; Tan, JS; Wishnow, RM	1
Mohammedi, I; Tigaud, S; Tournadre, JP	1
Chen, Y; Gao, L; Hou, F; Li, J	1
Gunderson, D; Kennedy, SL; Kern, W; Sachdeva, M; Sande, ER; Täuber, MG	1

Trials

5 trial(s) available for tazobactam and E coli Infections

Article	Year
Randomized controlled trial of piperacillin-tazobactam, cefepime and ertapenem for the treatment of urinary tract infection caused by extended-spectrum beta-lactamase-producing Escherichia coli. BMC infectious diseases, 2017, 06-07, Volume: 17, Issue:1 Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; beta-Lactamase Inhibitors; beta-Lactamases; beta-Lactams; Cefepime; Cephalosporins; Cross Infection; Ertapenem; Escherichia coli; Escherichia coli Infections; Female; Genotype; Humans; Male; Middle Aged; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Prospective Studies; Republic of Korea; Tazobactam; Urinary Tract Infections	2017
Efficacy of ceftolozane/tazobactam against urinary tract and intra-abdominal infections caused by ESBL-producing Escherichia coli and Klebsiella pneumoniae: a pooled analysis of Phase 3 clinical trials. The Journal of antimicrobial chemotherapy, 2017, Volume: 72, Issue:1 Topics: Administration, Intravenous; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Infective Agents, Urinary; beta-Lactamase Inhibitors; beta-Lactamases; Cephalosporins; Double-Blind Method; Escherichia coli; Escherichia coli Infections; Female; Genotype; Humans; Intraabdominal Infections; Klebsiella Infections; Klebsiella pneumoniae; Levofloxacin; Male; Meropenem; Metronidazole; Middle Aged; Penicillanic Acid; Tazobactam; Thienamycins; Treatment Outcome; Urinary Tract Infections; Young Adult	2017
Efficacy of ertapenem in the treatment of serious infections caused by Enterobacteriaceae: analysis of pooled clinical trial data. The Journal of antimicrobial chemotherapy, 2003, Volume: 51, Issue:5 Topics: Adult; Aged; beta-Lactams; Ceftriaxone; Cephalosporins; Community-Acquired Infections; Double-Blind Method; Drug Therapy, Combination; Enterobacteriaceae Infections; Ertapenem; Escherichia coli Infections; Humans; Lactams; Middle Aged; Multicenter Studies as Topic; Penicillanic Acid; Piperacillin; Tazobactam; Treatment Outcome; Urinary Tract Infections	2003
Treatment of hospitalized patients with complicated skin and skin structure infections: double-blind, randomized, multicenter study of piperacillin-tazobactam versus ticarcillin-clavulanate. The Piperacillin/Tazobactam Skin and Skin Structure Study Group. Antimicrobial agents and chemotherapy, 1993, Volume: 37, Issue:8 Topics: Bacteroides Infections; Clavulanic Acids; Double-Blind Method; Drug Therapy, Combination; Escherichia coli Infections; Female; Humans; Male; Middle Aged; Penicillanic Acid; Piperacillin; Skin Diseases, Bacterial; Staphylococcal Skin Infections; Staphylococcus aureus; Tazobactam; Ticarcillin	1993
A randomized controlled clinical trial on piperacillin/tazobactam versus ticarcillin/clavulanic acid for the treatment of bacterial infections. Chinese medical journal, 1998, Volume: 111, Issue:11 Topics: Adolescent; Adult; Anti-Bacterial Agents; Clavulanic Acid; Drug Therapy, Combination; Enzyme Inhibitors; Escherichia coli Infections; Female; Humans; Male; Penicillanic Acid; Penicillins; Piperacillin; Pneumonia; Respiratory Tract Infections; Tazobactam; Ticarcillin; Urinary Tract Infections	1998

Other Studies

38 other study(ies) available for tazobactam and E coli Infections

Article	Year
Structure-activity relationship of 6-methylidene penems bearing 6,5 bicyclic heterocycles as broad-spectrum beta-lactamase inhibitors: evidence for 1,4-thiazepine intermediates with C7 R stereochemistry by computational methods. Journal of medicinal chemistry, 2006, Jul-27, Volume: 49, Issue:15 Topics: Aldehydes; Animals; Anti-Bacterial Agents; beta-Lactam Resistance; beta-Lactamase Inhibitors; beta-Lactamases; Enterobacter aerogenes; Enterobacteriaceae Infections; Escherichia coli Infections; Gram-Negative Bacteria; Heterocyclic Compounds, 2-Ring; Imidazoles; Mice; Microbial Sensitivity Tests; Models, Molecular; Pyrazoles; Stereoisomerism; Structure-Activity Relationship; Thiazepines; Thiophenes	2006
Bloodstream infections caused by extended-spectrum-beta-lactamase- producing Escherichia coli: risk factors for inadequate initial antimicrobial therapy. Antimicrobial agents and chemotherapy, 2008, Volume: 52, Issue:9 Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Bacteremia; beta-Lactamases; Drug Resistance, Multiple, Bacterial; Escherichia coli; Escherichia coli Infections; Female; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Multivariate Analysis; Risk Factors; Treatment Failure	2008
Efficacy of piperacillin-tazobactam and cefotaxime against Escherichia coli hyperproducing TEM-1 in a mouse peritonitis infection model. International journal of antimicrobial agents, 2022, Volume: 59, Issue:4 Topics: Animals; Anti-Bacterial Agents; Antigens, CD; beta-Lactamases; Cefotaxime; Escherichia coli; Escherichia coli Infections; Mice; Microbial Sensitivity Tests; Neoplasm Proteins; Peritonitis; Piperacillin; Piperacillin, Tazobactam Drug Combination; Tazobactam	2022
High-risk lineages among extended-spectrum β-lactamase-producing Escherichia coli from extraintestinal infections in Maputo Central Hospital, Mozambique. International journal of antimicrobial agents, 2022, Volume: 60, Issue:4 Topics: Amoxicillin; Anti-Bacterial Agents; beta-Lactamases; Carbapenems; Cefotaxime; Ceftazidime; Ciprofloxacin; Clavulanic Acid; Escherichia coli; Escherichia coli Infections; Escherichia coli Proteins; Extraintestinal Pathogenic Escherichia coli; Gentamicins; Hospitals; Humans; Iron; Mozambique; Piperacillin; Tazobactam; Trimethoprim, Sulfamethoxazole Drug Combination	2022
Drug resistance characteristics and molecular typing of Escherichia coli isolates from neonates in class A tertiary hospitals: A multicentre study across China. The Journal of infection, 2022, Volume: 85, Issue:5 Topics: Anti-Bacterial Agents; Aztreonam; beta-Lactamases; Carbapenems; Cefotaxime; Child; Ciprofloxacin; Doxycycline; Drug Resistance; Escherichia coli; Escherichia coli Infections; Female; Humans; Infant, Newborn; Microbial Sensitivity Tests; Multilocus Sequence Typing; Piperacillin; Pregnancy; Tazobactam; Tertiary Care Centers; Trimethoprim, Sulfamethoxazole Drug Combination	2022
Genotypic resistance determined by whole genome sequencing versus phenotypic resistance in 234 Escherichia coli isolates. Scientific reports, 2023, 01-09, Volume: 13, Issue:1 Topics: Amikacin; Amoxicillin; Anti-Bacterial Agents; Cefepime; Cefotaxime; Ceftazidime; Ciprofloxacin; Clavulanic Acid; Escherichia coli; Escherichia coli Infections; Genotype; Gentamicins; Humans; Meropenem; Microbial Sensitivity Tests; Phenotype; Piperacillin; Retrospective Studies; Tazobactam; Tobramycin; Whole Genome Sequencing	2023
In vitro activity of ceftolozane/tazobactam against phenotypically defined extended-spectrum β-lactamase (ESBL)-positive isolates of Escherichia coli and Klebsiella pneumoniae isolated from hospitalized patients (SMART 2016). Diagnostic microbiology and infectious disease, 2020, Volume: 96, Issue:4 Topics: Anti-Bacterial Agents; beta-Lactamases; Cephalosporins; Cross Infection; Drug Resistance, Multiple, Bacterial; Epidemiological Monitoring; Escherichia coli; Escherichia coli Infections; Hospitalization; Humans; Klebsiella Infections; Klebsiella pneumoniae; Microbial Sensitivity Tests; Tazobactam	2020
Expression of CTX-M-15 limits the efficacy of ceftolozane/tazobactam against Escherichia coli in a high-inoculum murine peritonitis model. Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases, 2020, Volume: 26, Issue:10 Topics: Animals; Anti-Bacterial Agents; Bacterial Load; beta-Lactamase Inhibitors; beta-Lactamases; Carbapenem-Resistant Enterobacteriaceae; Cephalosporins; Disease Models, Animal; Escherichia coli; Escherichia coli Infections; Imipenem; Mice; Mice, Inbred ICR; Microbial Sensitivity Tests; Peritonitis; Tazobactam	2020
Piperacillin/tazobactam resistance in a clinical isolate of Escherichia coli due to IS26-mediated amplification of bla Nature communications, 2020, 10-01, Volume: 11, Issue:1 Topics: Anti-Bacterial Agents; beta-Lactamases; Chromosomes, Bacterial; DNA Transposable Elements; DNA, Bacterial; Drug Resistance, Multiple, Bacterial; Drug Therapy, Combination; Escherichia coli; Escherichia coli Infections; Escherichia coli Proteins; Gene Amplification; Gene Expression Regulation, Bacterial; Genome, Bacterial; Humans; Microbial Sensitivity Tests; Piperacillin; Polymorphism, Restriction Fragment Length; RNA, Ribosomal, 16S; Tazobactam; Whole Genome Sequencing	2020
Clinical syndromes and treatment location predict utility of carbapenem sparing therapies in ceftriaxone-non-susceptible Escherichia coli bloodstream infection. Annals of clinical microbiology and antimicrobials, 2020, Nov-30, Volume: 19, Issue:1 Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Azabicyclo Compounds; Bacteremia; Carbapenems; Ceftazidime; Ceftriaxone; Cephalosporins; Drug Combinations; Drug Resistance, Multiple, Bacterial; Escherichia coli; Escherichia coli Infections; Female; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Tazobactam	2020
Fungating groin mass in a woman with a history of follicular lymphoma. BMJ case reports, 2017, Aug-16, Volume: 2017 Topics: Anti-Bacterial Agents; Antineoplastic Agents; Ceftriaxone; Cyclophosphamide; Diagnosis, Differential; Escherichia coli Infections; Female; Groin; Humans; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Middle Aged; Penicillanic Acid; Piperacillin; Positron-Emission Tomography; Rituximab; Tazobactam; Tomography, X-Ray Computed; Vincristine	2017
Antibiotics susceptibility patterns of uropathogenic E. coli with special reference to fluoroquinolones in different age and gender groups. JPMA. The Journal of the Pakistan Medical Association, 2017, Volume: 67, Issue:8 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amikacin; Anti-Bacterial Agents; Cefoperazone; Child; Child, Preschool; Cross-Sectional Studies; Drug Resistance, Bacterial; Escherichia coli; Escherichia coli Infections; Female; Fluoroquinolones; Humans; Imipenem; Infant; Male; Meropenem; Microbial Sensitivity Tests; Middle Aged; Sulbactam; Tazobactam; Urinary Tract Infections; Young Adult	2017
Clinical efficacy and safety of cefepime-tazobactam in hospitalized patients in South India. Infectious diseases (London, England), 2018, Volume: 50, Issue:5 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; beta-Lactamases; Cefepime; Cephalosporins; Escherichia coli; Escherichia coli Infections; Female; Hospitalization; Humans; India; Klebsiella Infections; Klebsiella pneumoniae; Male; Middle Aged; Penicillanic Acid; Piperacillin; Tazobactam; Treatment Outcome; Young Adult	2018
Ceftolozane/tazobactam dose regimens in severely/morbidly obese patients with complicated intra-abdominal infection or complicated urinary tract infection. International journal of antimicrobial agents, 2018, Volume: 52, Issue:3 Topics: Anti-Bacterial Agents; Cephalosporins; Computer Simulation; Escherichia coli; Escherichia coli Infections; Female; Humans; Intraabdominal Infections; Klebsiella Infections; Klebsiella pneumoniae; Male; Microbial Sensitivity Tests; Middle Aged; Monte Carlo Method; Obesity, Morbid; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam; Urinary Tract Infections	2018
Activity of ceftolozane-tazobactam against Escherichia coli isolates from U.S. veterans (2011) in relation to co-resistance and sequence type 131 (ST131) H30 and H30Rx status. PloS one, 2018, Volume: 13, Issue:7 Topics: Anti-Bacterial Agents; Cephalosporins; Drug Resistance, Multiple, Bacterial; Escherichia coli; Escherichia coli Infections; Escherichia coli Proteins; Humans; Microbial Sensitivity Tests; Prevalence; Tazobactam; United States; United States Department of Veterans Affairs; Veterans	2018
Intramedullary Antibiotic Delivery for Emphysematous Osteomyelitis of the Femur. Orthopedics, 2019, Jan-01, Volume: 42, Issue:1 Topics: Anti-Bacterial Agents; Bone Cements; Bone Nails; Emphysema; Escherichia coli; Escherichia coli Infections; Female; Femur; Humans; Middle Aged; Osteomyelitis; Piperacillin; Tazobactam	2019
ESBLs and resistance to ceftazidime/avibactam and ceftolozane/tazobactam combinations in Escherichia coli and Pseudomonas aeruginosa. The Journal of antimicrobial chemotherapy, 2019, 07-01, Volume: 74, Issue:7 Topics: Azabicyclo Compounds; beta-Lactamase Inhibitors; beta-Lactamases; Ceftazidime; Cephalosporins; Drug Combinations; Drug Resistance, Multiple, Bacterial; Escherichia coli; Escherichia coli Infections; Humans; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam	2019
Use of continuous infusion ceftolozane-tazobactam with therapeutic drug monitoring in a patient with cystic fibrosis. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2019, Apr-08, Volume: 76, Issue:8 Topics: Adult; Anti-Bacterial Agents; Cephalosporins; Cystic Fibrosis; Drug Administration Schedule; Drug Monitoring; Drug Resistance, Multiple, Bacterial; Escherichia coli; Escherichia coli Infections; Female; Humans; Infusions, Intravenous; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam; Treatment Outcome	2019
The impact of the increased use of piperacillin/tazobactam on the selection of antibiotic resistance among invasive Escherichia coli and Klebsiella pneumoniae isolates. International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases, 2013, Volume: 17, Issue:8 Topics: Anti-Bacterial Agents; Cross Infection; Drug Resistance, Bacterial; Escherichia coli; Escherichia coli Infections; Humans; Klebsiella Infections; Klebsiella pneumoniae; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Tazobactam	2013
Impact of the MIC of piperacillin-tazobactam on the outcome of patients with bacteremia due to extended-spectrum-β-lactamase-producing Escherichia coli. Antimicrobial agents and chemotherapy, 2013, Volume: 57, Issue:7 Topics: Aged; Anti-Bacterial Agents; Bacteremia; beta-Lactamases; Cohort Studies; Drug Therapy, Combination; Enzyme Inhibitors; Escherichia coli; Escherichia coli Infections; Humans; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Tazobactam; Treatment Outcome; Urinary Tract Infections	2013
Pharmacokinetics-pharmacodynamics of tazobactam in combination with ceftolozane in an in vitro infection model. Antimicrobial agents and chemotherapy, 2013, Volume: 57, Issue:6 Topics: Anti-Bacterial Agents; Area Under Curve; beta-Lactamases; Cephalosporins; Dose-Response Relationship, Drug; Drug Therapy, Combination; Escherichia coli; Escherichia coli Infections; Humans; Microbial Sensitivity Tests; Models, Biological; Molecular Sequence Data; Penicillanic Acid; Real-Time Polymerase Chain Reaction; Sequence Analysis, DNA; Tazobactam	2013
Pharmacological basis of β-lactamase inhibitor therapeutics: tazobactam in combination with Ceftolozane. Antimicrobial agents and chemotherapy, 2013, Volume: 57, Issue:12 Topics: Anti-Bacterial Agents; beta-Lactamases; Cephalosporins; Colony Count, Microbial; Computer Simulation; Drug Administration Schedule; Drug Combinations; Drug Dosage Calculations; Escherichia coli; Escherichia coli Infections; Gene Expression; Half-Life; Humans; Klebsiella Infections; Klebsiella pneumoniae; Microbial Sensitivity Tests; Models, Statistical; Penicillanic Acid; Plasmids; Tazobactam	2013
In vitro activity of ceftolozane-tazobactam as determined by broth dilution and agar diffusion assays against recent U.S. Escherichia coli isolates from 2010 to 2011 carrying CTX-M-type extended-spectrum β-lactamases. Journal of clinical microbiology, 2014, Volume: 52, Issue:11 Topics: Anti-Bacterial Agents; Cephalosporins; Escherichia coli; Escherichia coli Infections; Humans; Microbial Sensitivity Tests; Penicillanic Acid; Tazobactam; United States	2014
Role of the culture medium in porin expression and piperacillin-tazobactam susceptibility in Escherichia coli. Journal of medical microbiology, 2015, Volume: 64, Issue:11 Topics: Anti-Bacterial Agents; beta-Lactamases; Culture Media; Escherichia coli; Escherichia coli Infections; Escherichia coli Proteins; Humans; Penicillanic Acid; Piperacillin; Porins; Tazobactam	2015
Characterization of Piperacillin/Tazobactam-Resistant Klebsiella oxytoca Recovered from a Nosocomial Outbreak. PloS one, 2015, Volume: 10, Issue:11 Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; beta-Lactamases; beta-Lactams; Cross Infection; Disease Outbreaks; Drug Resistance, Multiple, Bacterial; Escherichia coli; Escherichia coli Infections; Female; Humans; Japan; Klebsiella Infections; Klebsiella oxytoca; Male; Microbial Sensitivity Tests; Middle Aged; Multilocus Sequence Typing; Penicillanic Acid; Piperacillin; Tazobactam	2015
Antimicrobial susceptibility of well-characterised multiresistant CTX-M-producing Escherichia coli: failure of automated systems to detect resistance to piperacillin/tazobactam. International journal of antimicrobial agents, 2008, Volume: 32, Issue:4 Topics: Anti-Bacterial Agents; Automation; beta-Lactamases; Deoxyribonucleases, Type II Site-Specific; Drug Resistance, Multiple, Bacterial; Electrophoresis, Gel, Pulsed-Field; Escherichia coli; Escherichia coli Infections; Escherichia coli Proteins; Humans; Isoelectric Focusing; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Polymerase Chain Reaction; Sequence Analysis, DNA; Tazobactam	2008
Protective effect of citropin 1.1 and tazobactam-piperacillin against oxidative damage and lethality in mice models of gram-negative sepsis. The Journal of surgical research, 2011, Volume: 171, Issue:2 Topics: Amphibian Proteins; Animals; Anti-Bacterial Agents; Anti-Infective Agents; Antimicrobial Cationic Peptides; Disease Models, Animal; Drug Therapy, Combination; Enzyme Inhibitors; Escherichia coli; Escherichia coli Infections; Lipopolysaccharides; Male; Mice; Mice, Inbred BALB C; Oxidative Stress; Penicillanic Acid; Piperacillin; Tazobactam	2011
In vitro activity of CXA-101 plus tazobactam (CXA-201) against CTX-M-14- and CTX-M-15-producing Escherichia coli and Klebsiella pneumoniae. Diagnostic microbiology and infectious disease, 2011, Volume: 70, Issue:1 Topics: Anti-Bacterial Agents; Bacterial Typing Techniques; beta-Lactamases; Cephalosporins; Escherichia coli; Escherichia coli Infections; Genotype; Humans; Klebsiella Infections; Klebsiella pneumoniae; Microbial Sensitivity Tests; Molecular Typing; Penicillanic Acid; Tazobactam	2011
In vivo comparison of CXA-101 (FR264205) with and without tazobactam versus piperacillin-tazobactam using human simulated exposures against phenotypically diverse gram-negative organisms. Antimicrobial agents and chemotherapy, 2012, Volume: 56, Issue:1 Topics: Animals; Anti-Bacterial Agents; beta-Lactamases; Cephalosporins; Colony Count, Microbial; Disease Models, Animal; Drug Combinations; Drug Resistance, Bacterial; Escherichia coli; Escherichia coli Infections; Female; Humans; Klebsiella Infections; Klebsiella pneumoniae; Mice; Mice, Inbred ICR; Microbial Sensitivity Tests; Penicillanic Acid; Phenotype; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam; Thigh	2012
Risk factors for infection or colonization with CTX-M extended-spectrum-β-lactamase-positive Escherichia coli. Antimicrobial agents and chemotherapy, 2012, Volume: 56, Issue:11 Topics: Adult; Aged; Anti-Bacterial Agents; beta-Lactam Resistance; beta-Lactamases; Case-Control Studies; Escherichia coli; Escherichia coli Infections; Female; Fluoroquinolones; Humans; Male; Middle Aged; Penicillanic Acid; Piperacillin; Regression Analysis; Risk Factors; Tazobactam	2012
Exploring the effectiveness of tazobactam against ceftazidime resistant Escherichia coli: insights from the comparison between susceptibility testing and beta-lactamase inhibition. FEMS microbiology letters, 2004, May-01, Volume: 234, Issue:1 Topics: Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamase Inhibitors; beta-Lactamases; beta-Lactams; Cefepime; Ceftazidime; Cephalosporins; Drug Resistance, Bacterial; Drug Therapy, Combination; Enzyme Inhibitors; Ertapenem; Escherichia coli; Escherichia coli Infections; Lactams; Microbial Sensitivity Tests; Penicillanic Acid; Tazobactam	2004
Impact of tazobactam pharmacokinetics on the antimicrobial effect of piperacillin-tazobactam combinations. International journal of antimicrobial agents, 2004, Volume: 23, Issue:5 Topics: Anti-Bacterial Agents; beta-Lactamases; Colony Count, Microbial; Drug Resistance, Bacterial; Drug Therapy, Combination; Enzyme Inhibitors; Escherichia coli; Escherichia coli Infections; Humans; Mathematics; Models, Biological; Penicillanic Acid; Piperacillin; Tazobactam; Treatment Outcome	2004
Successful treatment and limb salvage of mucor necrotizing fasciitis after kidney transplantation with posaconazole. Hawaii medical journal, 2007, Volume: 66, Issue:3 Topics: Alcaligenes; Amphotericin B; Amputation, Surgical; Antifungal Agents; Cefazolin; Combined Modality Therapy; Debridement; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Drug Combinations; Drug Resistance, Multiple, Fungal; Escherichia coli Infections; Fatal Outcome; Fluconazole; Gangrene; Graft Rejection; Gram-Negative Bacterial Infections; Humans; Immunocompromised Host; Immunosuppressive Agents; Kidney Transplantation; Leg; Leg Ulcer; Male; Middle Aged; Mucor; Mucormycosis; Penicillanic Acid; Phosphatidylcholines; Phosphatidylglycerols; Piperacillin; Postoperative Complications; Pyrimidines; Renal Dialysis; Reoperation; Sepsis; Skin Transplantation; Tazobactam; Triazoles; Voriconazole	2007
Efficacy of the bovine antimicrobial peptide indolicidin combined with piperacillin/tazobactam in experimental rat models of polymicrobial peritonitis. Critical care medicine, 2008, Volume: 36, Issue:1 Topics: Animals; Anti-Infective Agents; Antimicrobial Cationic Peptides; Disease Models, Animal; Drug Therapy, Combination; Enterococcus faecalis; Escherichia coli; Escherichia coli Infections; Gram-Positive Bacterial Infections; Male; Microbial Sensitivity Tests; Penicillanic Acid; Peritonitis; Piperacillin; Rats; Rats, Wistar; Shock, Septic; Tazobactam; Treatment Outcome	2008
Incidence and impact on clinical outcome of infections with piperacillin/tazobactam resistant Escherichia coli in ICU: a retrospective study. BMC infectious diseases, 2008, May-17, Volume: 8 Topics: Anti-Bacterial Agents; beta-Lactamases; Cohort Studies; Cross Infection; Drug Resistance, Multiple, Bacterial; Escherichia coli; Escherichia coli Infections; Female; France; Humans; Incidence; Intensive Care Units; Length of Stay; Male; Middle Aged; Penicillanic Acid; Piperacillin; Retrospective Studies; Tazobactam; Treatment Outcome	2008
[Bacteremia by Escherichia coli resistant to amoxycillin/clavulanic acid, ampicillin/sulbactam and piperacillin/tazobactam]. Medicina clinica, 1994, Feb-12, Volume: 102, Issue:5 Topics: Aged; Ampicillin; Clavulanic Acid; Clavulanic Acids; Drug Resistance, Microbial; Drug Therapy, Combination; Escherichia coli; Escherichia coli Infections; Female; Humans; Penicillanic Acid; Sulbactam; Tazobactam	1994
Emergence of piperacillin/tazobactam-resistant Escherichia coli. Intensive care medicine, 2000, Volume: 26, Issue:10 Topics: beta-Lactamase Inhibitors; Communicable Diseases, Emerging; Cross Infection; Drug Resistance, Microbial; Drug Therapy, Combination; Escherichia coli Infections; France; Humans; Infection Control; Intensive Care Units; Patient Selection; Penicillanic Acid; Penicillins; Piperacillin; Tazobactam	2000
Evaluation of piperacillin-tazobactam in experimental meningitis caused by a beta-lactamase-producing strain of K1-positive Escherichia coli. Antimicrobial agents and chemotherapy, 1990, Volume: 34, Issue:5 Topics: Animals; Anti-Bacterial Agents; beta-Lactamase Inhibitors; Dose-Response Relationship, Drug; Drug Combinations; Escherichia coli; Escherichia coli Infections; Meningitis; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Rabbits; Tazobactam	1990